REPORTING TIMELINES TO OHSN-REB

Type of Event	Reporting Timeline* to the REB
**must be considered related or possibly related to study intervention/drug	*within the study team's awareness
	of the event/report
**Local (internal) Serious Adverse Event/ Unanticipated Problem that is fatal	3 days
or life threatening	
**Local (internal) Serious Adverse Event/ Unanticipated Problem (non-fatal,	7 days
non-life threatening)	
** Non-Local (external) Serious Adverse Event/ Unanticipated Problem that	7 days
requires change(s) to study documents and/or notification to participants	
Periodic Safety Update Reports or Safety Summary Reports	15 days
Examples:	
• SU-ADR Listings	
• CIOMS	
Other Unanticipated Problem	15 days
Examples:	
Updated Safety Information:	
 DSMB/C Report 	
 Interim Analysis Results 	
Pregnant Partner	
• Sponsor Safety Notice, Action Letter or Alert that would cause the sponsor	
to modify the Investigator's Brochure, the research, or the consent form,	
or would prompt other action by the REB to ensure protection of research	
participants	
Information that is published from another research project that shows	
that an arm of the research study is of no therapeutic value	
• A change in Health Canada or FDA safety labelling therapy or withdrawal	
from marketing of a drug, device, health product, genetic therapy or	
biologic used in research	

• Any unanticipated problem or other event that could significantly impact the conduct of the research at the site (e.g.: concern of non-compliance)

Major Protocol Deviation

Privacy Breach

Relevant Audit or Inspection Findings

Research Participant Complaint

REPORTING TIMELINES TO SPONSOR

Type of Event	Reporting Timeline* to Sponsor	
**must be considered related or possibly related to study intervention/drug	*within the study team awareness of the event/report	
**Local (internal) Serious Adverse Event/ Unanticipated Problem	24 hours	
	(if OHRI is sponsor, report to	
	<u>clinicalresearchadmin@ohri.ca</u>)	
**Individual Non-Local (external) Serious Adverse Event/ Unanticipated	24 hours	
Problem that requires change(s) to study documents and/or notification to participants	(if OHRI is sponsor, report to	
	<u>clinicalresearchadmin@ohri.ca</u>)	

15 days

Within 24 hours **Note,** for TOH/OHRI, it is within 24 hours of TOH Privacy Office confirming incident is a privacy breach

15 days

Within 24 hours

If study involves Drug(s)	Reporting Timeline* to Health Canada
& Investigator/OHRI/UOHI is the Study Sponsor	
	*within the study team awareness
	of the event/report
Serious Unexpected–Adverse Drug Reaction (SU-ADR)	15 days
SU-ADR that is fatal or life threatening	7 days
Ŭ	with follow-up within 8 days
If study involves Natural Health Product or Radiopharmaceutical(s)	Reporting Timeline* to Health Canada
& Investigator/OHRI/UOHI is Study Sponsor	*within the study team awareness
	of the event/report
Serious Adverse Drug Reaction, expected or unexpected	15 days
SADR that is fatal or life threatening	7 days
	with follow-up within 8 days
If study involves an	Reporting Timeline* to Health Canada
Investigational Medical Device	
	*within the study team awareness of the event/report
Mandatory Problem Reporting timeline for Investigator's who are the sponsor	
wandatory roblem reporting timeline for investigator's who are the sponsor	· · · · ·
Serious Adverse Event that has led to death or a serious deterioration in the	10 days
state of health of a patient, user or other person	
	30 days
SAE that has not led to the death or serious deterioration in the health of a	
patient, user or other person, but could do so were it to recur. Please review	

 Mandatory Problem Reporting timeline for local Investigator's participating in a device trial
 72 hours

 Mandatory problem reporting for serious adverse event related to the device that:
 72 hours

 • is related to failure of the device, deterioration in effectiveness or inadequacy in labelling or direction in use
 and Importer as well as Health Canada

 • led to death or serious deterioration of heath of patient, user or other person or could do so were it to recur. Medical Device Regulations
 Subsection 81 (k)(v)

Note: The REB guidelines for reporting serious adverse events / adverse drug reactions/ unanticipated problems apply when the OHSN-REB is the Board of Record for the research study. If OHSN-REB is not the Board of Record for the research study, the researcher will refer to the serious adverse event /unanticipated problem reporting requirements as stated in the Board of Record Agreement for the research study.

Revision History		
Version Number	Effective Date	Summary of Changes
N/A	September 29, 2023	No revisions required to appendix 1 with version N2 CAREB SOP
		404.004.
Version 2	January 12, 2022	Added note into 'Privacy Breach' line item; updated reporting
		timeline for participant complaints from 15 days to 24 hours.
Version 1	October 1, 2019	Initial Version